Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 4/2017

01.04.2017 | Movement Disorders (S Fox, Section Editor)

α-Synuclein and Parkinsonism: Updates and Future Perspectives

verfasst von: Kaie Rosborough, Neha Patel, Lorraine V. Kalia

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Mutations in the SNCA gene, which encodes the α-synuclein protein, were the first discovered genetic causes of familial parkinsonism with Lewy pathology. To date, six different SNCA missense mutations as well as multiplications are known to cause parkinsonism. For this review, we performed a literature search to identify all published cases of SNCA-related parkinsonism to provide an updated summary of the clinical and neuropathological features of parkinsonism due to SNCA mutations. Familial parkinsonism associated with SNCA is rare, but α-synuclein aggregation is a core feature of sporadic parkinsonism, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Research into α-synuclein and parkinsonism has impacted how we define the pathology and understand the pathogenesis of Parkinson’s disease and related neurodegenerative disorders. We briefly discuss some of the lessons we have learned from research into the physiological role of α-synuclein and its pathological links to neurodegeneration and parkinsonism.
Literatur
1.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–7.PubMedCrossRef
2.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839–40.PubMedCrossRef
3.
Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—a new disease? Clin Neuropathol. 1984;3:185–92.PubMed
4.
Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol. 1999;155:1241–51.PubMedPubMedCentralCrossRef
5.
6.
Farrer M, Wavrant-De Vrieze F, Crook R, Boles L, Perez-Tur J, Hardy J, et al. Low frequency of alpha-synuclein mutations in familial Parkinson’s disease. Ann Neurol. 1998;43:394–7.PubMedCrossRef
7.
Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18:R48–59.PubMedCrossRef
8.
Wang C, Zhao C, Li D, Tian Z, Lai Y, Diao J, et al. Versatile structures of α-synuclein. Front Mol Neurosci. 2016;9:48.PubMedPubMedCentral
9.
Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM-Y. Alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res. 2000;62:9–14.PubMedCrossRef
10.
Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62:964–70.PubMedPubMedCentralCrossRef
11.
Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, et al. Expression of α-synuclein, a presynaptic protein implicated in Parkinson’s disease, in erythropoietic lineage. Biochem Biophys Res Commun. 2007;358:104–10.PubMedCrossRef
12.
Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, et al. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson’s disease. PLoS One. 2013;8:e71634.PubMedPubMedCentralCrossRef
13.
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, et al. The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467–75.PubMedCrossRef
14.
15.
Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239–52.PubMedCrossRef
16.
Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biogeosciences. 2010;26:211–33.CrossRef
17.
Fusco G, Pape T, Stephens AD, Mahou P, Costa AR, Kaminski CF, et al. Structural basis of synaptic vesicle assembly promoted by α-synuclein. Nat Commun. 2016;7:12563.PubMedPubMedCentralCrossRef
18.
Calo L, Wegrzynowicz M, Santivañez-Perez J, Grazia SM. Synaptic failure and α-synuclein. Mov Disord. 2016;31:169–77.PubMedCrossRef
19.
• Cartelli D, Aliverti A, Barbiroli A, Santambrogio C, Ragg EM, Casagrande FVM, et al. α-Synuclein is a novel microtubule dynamase. Sci Rep. 2016;6:33289. Cartelli et al. demonstrate that α-synuclein can bind to tubulin and thereby regulate microtubule formation in vitro. Five of the six α-synuclein missense mutations associated with parkinsonism are located within the putative region that binds to tubulin and thus may lead to microtubule impairment.PubMedPubMedCentralCrossRef
20.
Shameli A, Xiao W, Zheng Y, Shyu S, Sumodi J, Meyerson HJ, et al. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology. 2016;221:333–40.PubMedCrossRef
21.
Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012;14:38–48.CrossRef
22.
Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013;73:155–69.PubMedCrossRef
23.
•• Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016;8:342ra78. Di Maio et al. demonstrate that α-synuclein binds to the mitochondrial protein TOM20 in rodent models of PD which impairs the ability of mitochondria to import proteins required for normal mitochondrial function. This work reveals a novel mechanism by which α-synuclein may cause cytotoxicity.PubMedPubMedCentralCrossRef
24.
Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, et al. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci. 2012;32:3306–20.PubMedPubMedCentralCrossRef
25.
Hinault M-P, Cuendet AFH, Mattoo RUH, Mensi M, Dietler G, Lashuel HA, et al. Stable α-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem. 2010;285:38173–82.PubMedPubMedCentralCrossRef
26.
Xilouri M, Brekk OR, Stefanis L. Autophagy and alpha-synuclein: relevance to Parkinson’s disease and related synucleopathies. Mov Disord. 2016;31:178–92.PubMedCrossRef
27.
28.
Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain. 2017;140:266-78.
29.
Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998;18:106–8.PubMedCrossRef
30.
Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of α-synuclein causes parkinson and Lewy body dementia. Ann Neurol. 2004;55:164–73.PubMedCrossRef
31.
Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013;28:811–3.PubMedCrossRef
32.
Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology. 2013;80:1062–4.PubMedPubMedCentralCrossRef
33.
Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, et al. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy? Acta Neuropathol. 2013;125:753–69.PubMedPubMedCentralCrossRef
34.
Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, et al. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459–71.PubMedCrossRef
35.
• Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, et al. A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson’s disease-type pathology. Neurobiol Aging. 2014;35:2180.e1-2180.e5. Pasanen et al. made the recent discovery of a novel SNCA missense mutation associated with familial parkinsonism, almost 20 years after the first SNCA mutation was identified. This finding may indicate that other SNCA mutations remain to be discovered.CrossRef
36.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.PubMedCrossRef
37.
38.
Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology. 2004;62:1835–8.PubMedCrossRef
39.
Krüger R, Kuhn W, Leenders KL, Sprengelmeyer R, Müller T, Woitalla D, et al. Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology. 2001;56:1355–62.
40.
Seidel K, Schöls L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, et al. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann Neurol. 2010;67:684–9.PubMedCrossRef
41.
Tijero B, Gómez-Esteban JC, Lezcano E, Fernández-González C, Somme J, Llorens V, et al. Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the α synuclein gene. Parkinsonism Relat Disord. 2013;19:95–100.PubMedCrossRef
42.
Pimentel MMG, Rodrigues FC, Leite MAA, Campos Júnior M, Rosso AL, Nicaretta DH, et al. Parkinson disease: α-synuclein mutational screening and new clinical insight into the p.E46K mutation. Parkinsonism Relat Disord. 2015;21:586–9.PubMedCrossRef
43.
Kiely AP, Ling H, Asi YT, Kara E, Proukakis C, Schapira AH, et al. Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodegener. 2015;10:41.PubMedPubMedCentralCrossRef
44.
Tokutake T, Ishikawa A, Yoshimura N, Miyashita A, Kuwano R, Nishizawa M, et al. Clinical and neuroimaging features of patient with early-onset Parkinson’s disease with dementia carrying SNCA p.G51D mutation. Parkinsonism Relat Disord. 2014;20:262–4.PubMedCrossRef
45.
Martikainen MH, Päivärinta M, Hietala M, Kaasinen V. Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation. Neurol Genet. 2015;1:e27.PubMedPubMedCentralCrossRef
46.
Picillo M, Munhoz R, Kalia LV. Early-onset parkinsonism, behavioral and cognitive issues (unpublished).
47.
Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson’s disease. Ann Neurol. 1990;27:276–82.PubMedCrossRef
48.
Markopoulou K, Wszolek ZK, Pfeiffer RF. A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol. 1995;38:373–8.PubMedCrossRef
49.
Athanassiadou A, Voutsinas G, Psiouri L, Leroy E, Polymeropoulos MH, Ilias A, et al. Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum Genet. 1999;65:555–8.PubMedPubMedCentralCrossRef
50.
Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastasopoulos I. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology. 1999;52:651–4.PubMedCrossRef
51.
Papapetropoulos S, Paschalis C, Athanassiadou A, Papadimitriou A, Ellul J, Polymeropoulos MH, et al. Clinical phenotype in patients with α-synuclein Parkinson’s disease living in Greece in comparison with patients with sporadic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70:662–5.PubMedPubMedCentralCrossRef
52.
Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α-synuclein mutation. Ann Neurol. 2001;49:313–9.PubMedCrossRef
53.
Bostantjopoulou S, Katsarou Z, Papadimitriou A, Veletza V, Hatzigeorgiou G, Lees A. Clinical features of parkinsonian patients with the α-synuclein (G209A) mutation. Mov Disord. 2001;16:1007–13.PubMedCrossRef
54.
Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM-Y, et al. Concurrence of α-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 2002;104:7–11.PubMedCrossRef
55.
Papapetropoulos S, Ellul J, Paschalis C, Athanassiadou A, Papadimitriou A, Papapetropoulos T. Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson’s disease in comparison with other forms of familial Parkinson’s disease in Greece. Eur J Neurol. 2003;10:281–6.PubMedCrossRef
56.
Michell AW, Barker RA, Raha SK, Raha-Chowdhury R. A case of late onset sporadic Parkinson’s disease with an A53T mutation in alpha-synuclein. J Neurol Neurosurg Psychiatry. 2005;76:596–7.PubMedPubMedCentralCrossRef
57.
Yamaguchi K, Cochran EJ, Murrell JR, Polymeropoulos MH, Shannon KM, Crowther RA, et al. Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the α-synuclein gene. Acta Neuropathol. 2005;110:298–305.PubMedCrossRef
58.
Morfis L, Cordato DJ. Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation. J Clin Neurosci. 2006;13:942–4.PubMedCrossRef
59.
Ki C-S, Stavrou E, Davanos N, Lee W, Chung E, Kim J-Y, et al. The Ala53Thr mutation in the α-synuclein gene in a Korean family with Parkinson disease. Clin Genet. 2007;71:471–3.PubMedCrossRef
60.
Markopoulou K, Dickson DW, McComb RD, Wszolek ZK, Katechalidou L, Avery L, et al. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson’s disease. Acta Neuropathol. 2008;116:25–35.PubMedPubMedCentralCrossRef
61.
Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, et al. A Swedish family with de novo α-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord. 2009;15:627–32.PubMedPubMedCentralCrossRef
62.
Fujishiro H, Imamura AY, Lin W-L, Uchikado H, Mark MH, Golbe LI, et al. Diversity of pathological features other than Lewy bodies in familial Parkinson’s disease due to SNCA mutations. Am J Neurodegener Dis. 2013;2:266–75.PubMedPubMedCentral
63.
Bozi M, Papadimitriou D, Antonellou R, Moraitou M, Maniati M, Vassilatis DK, et al. Genetic assessment of familial and early-onset Parkinson’s disease in a Greek population. Eur J Neurol. 2014;21:963–8.PubMedCrossRef
64.
Ricciardi L, Petrucci S, Di Giuda D, Serra L, Spanò B, Sensi M, et al. The Contursi family 20 years later: intrafamilial phenotypic variability of the SNCA p.A53T mutation. Mov Disord. 2016;31:257–8.PubMedCrossRef
65.
Papadimitriou D, Antonelou R, Miligkos M, Maniati M, Papagiannakis N, Bostantjopoulou S, et al. Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study. Mov Disord. 2016;31:1226–30.PubMedCrossRef
66.
Xiong W-X, Sun Y-M, Guan R-Y, Luo S-S, Chen C, An Y, et al. The heterozygous A53T mutation in the alpha-synuclein gene in a Chinese Han patient with Parkinson disease: case report and literature review. J Neurol. 2016;263:1984–92.PubMedCrossRef
67.
Tambasco N, Nigro P, Romoli M, Prontera P, Simoni S, Calabresi P. A53T in a parkinsonian family: a clinical update of the SNCA phenotypes. J Neural Transm. 2016;123:1301–7.PubMedCrossRef
68.
Ishikawa A, Takahashi H, Tanaka H, Hayashi T, Tsuji S. Clinical features of familial diffuse Lewy body disease. Eur Neurol. 1997;38(1):34–8.PubMedCrossRef
69.
Wakabayashi K, Hayashi S, Ishikawa A, Hayashi T, Okuizumi K, Tanaka H, et al. Autosomal dominant diffuse Lewy body disease. Acta Neuropathol. 1998;96:207–10.PubMedCrossRef
70.
Chartier-Harlin M-C, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. α-Synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004;364:1167–9.PubMedCrossRef
71.
Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Agid Y, et al. Causal relation between α-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004;364:1169–71.PubMedCrossRef
72.
Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. Clinical heterogeneity of α-synuclein gene duplication in Parkinson’s disease. Ann Neurol. 2006;59:298–309.PubMedCrossRef
73.
Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson E-M, Schüle B, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology. 2007;68:916–22.PubMedCrossRef
74.
Obi T, Nishioka K, Ross OA, Terada T, Yamazaki K, Sugiura A, et al. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology. 2008;70:238–41.PubMedCrossRef
75.
Uchiyama T, Ikeuchi T, Ouchi Y, Sakamoto M, Kasuga K, Shiga A, et al. Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. Neurology. 2008;71:1289–91.PubMedCrossRef
76.
Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, Tan C-F, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol. 2008;65:514–9.PubMedCrossRef
77.
Ahn T-B, Kim SY, Kim JY, Park S-S, Lee DS, Min HJ, et al. α-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;70:43–9.PubMedCrossRef
78.
Brueggemann N, Odin P, Gruenewald A, Tadic V, Hagenah J, Seidel G, et al. α-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;71:1294.PubMedCrossRef
79.
Troiano AR, Cazeneuve C, Le Ber I, Bonnet A-M, Lesage S, Brice A. α-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology. 2008;71:1295.PubMedCrossRef
80.
Ibáñez P, Lesage S, Janin S, Lohmann E, Durif F, Destée A, et al. α-Synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol. 2009;66:102–8.PubMedCrossRef
81.
Nishioka K, Ross OA, Ishii K, Kachergus JM, Ishiwata K, Kitagawa M, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord. 2009;24:1811–9.PubMedCrossRef
82.
Puschmann A, Wszolek ZK, Farrer M, Gustafson L, Widner H, Nilsson C. Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus? Parkinsonism Relat Disord. 2009;15:390–2.PubMedCrossRef
83.
Sironi F, Trotta L, Antonini A, Zini M, Ciccone R, Della Mina E, et al. α-Synuclein multiplication analysis in Italian familial Parkinson disease. Parkinsonism Relat Disord. 2010;16:228–31.PubMedCrossRef
84.
Shin CW, Kim HJ, Park SS, Kim SY, Kim JY, Jeon BS. Two Parkinson’s disease patients with alpha-synuclein gene duplication and rapid cognitive decline. Mov Disord. 2010;25:957–9.PubMedCrossRef
85.
Ling H, Braschinsky M, Taba P, Lüüs S-M, Doherty K, Hotter A, et al. Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients. Mov Disord. 2011;26:1337–40.PubMedCrossRef
86.
Szamosi A, Nagy H, Kéri S. Delay discounting of reward and caudate nucleus volume in individuals with α-synuclein gene duplication before and after the development of Parkinson’s disease. Neurodegener Dis. 2012;11:72–8.PubMedCrossRef
87.
Meeus B, Verstraeten A, Crosiers D, Engelborghs S, Van den Broeck M, Mattheijssens M, et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes? Neurobiol Aging. 2012;33:629.e5-629.e18.PubMedCrossRef
88.
Itokawa K, Sekine T, Funayama M, Tomiyama H, Fukui M, Yamamoto T, et al. A case of α-synuclein gene duplication presenting with head-shaking movements. Mov Disord. 2013;28:384–7.PubMedCrossRef
89.
Elia AE, Petrucci S, Fasano A, Guidi M, Valbonesi S, Bernardini L, et al. Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. Mov Disord. 2013;28:813–7.PubMedCrossRef
90.
Darvish H, Movafagh A, Omrani MD, Firouzabadi SG, Azargashb E, Jamshidi J, et al. Detection of copy number changes in genes associated with Parkinson’s disease in Iranian patients. Neurosci Lett. 2013;551:75–8.PubMedCrossRef
91.
Perandones C, Giugni JC, Calvo DS, Raina GB, De Jorge LL, Volpini V, et al. Mosaicism of alpha-synuclein gene rearrangements: report of two unrelated cases of early-onset parkinsonism. Parkinsonism Relat Disord. 2014;20:558–61.PubMedCrossRef
92.
Kara E, Kiely AP, Proukakis C, Giffin N, Love S, Hehir J, et al. A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and parkinsonism: phenotype-genotype correlations. JAMA Neurol. 2014;71:1162.PubMedPubMedCentralCrossRef
93.
Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Autosomal dominant Parkinson’s disease caused by SNCA duplications. Parkinsonism Relat Disord. 2016;22:S1–6.PubMedCrossRef
94.
Takamura S, Ikeda A, Nishioka K, Furuya H, Tashiro M, Matsushima T, et al. Schizophrenia as a prodromal symptom in a patient harboring SNCA duplication. Parkinsonism Relat Disord. 2016;25:108–9.PubMedCrossRef
95.
Waters CH, Miller CA. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol. 1994;35:59–64.PubMedCrossRef
96.
Muenter MD, Forno LS, Hornykiewicz O, Kish SJ, Maraganore DM, Caselli RJ, et al. Hereditary form of parkinsonism—dementia. Ann Neurol. 1998;43:768–81.PubMedCrossRef
97.
Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol. 2000;99:663–72.PubMedCrossRef
98.
Farrer M, Kachergus J, Forno L, Lincoln S, Wang D-S, Hulihan M, et al. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann Neurol. 2004;55:174–9.PubMedCrossRef
99.
Sekine T, Kagaya H, Funayama M, Li Y, Yoshino H, Tomiyama H, et al. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov Disord. 2010;25:2871–5.PubMedCrossRef
100.
Keyser RJ, Lombard D, Veikondis R, Carr J, Bardien S. Analysis of exon dosage using MLPA in South African Parkinson’s disease patients. Neurogenetics. 2010;11:305–12.PubMedCrossRef
101.
Kojovic M, Bologna M, Kassavetis P, Murase N, Palomar FJ, Berardelli A, et al. Functional reorganization of sensorimotor cortex in early Parkinson disease. Neurology. 2012;78:1441–8.PubMedPubMedCentralCrossRef
102.
Olgiati S, Thomas A, Quadri M, Breedveld GJ, Graafland J, Eussen H, et al. Early-onset parkinsonism caused by alpha-synuclein gene triplication: clinical and genetic findings in a novel family. Parkinsonism Relat Disord. 2015;21:981–6.PubMedCrossRef
103.
Ferese R, Modugno N, Campopiano R, Santilli M, Zampatti S, Giardina E, et al. Four copies of SNCA responsible for autosomal dominant Parkinson’s disease in two Italian siblings. Park Dis. 2015;2015:1–6.CrossRef
104.
105.
Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583–90.PubMedCrossRef
106.
Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, et al. The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82:1112–8.PubMedCrossRef
107.
Kalia LV, Lang AE, Hazrati L-N, Fujioka S, Wszolek ZK, Dickson DW, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015;72:100–5.PubMedPubMedCentralCrossRef
108.
Doherty KM, Silveira-Moriyama L, Parkkinen L, Healy DG, Farrell M, Mencacci NE, et al. Parkin disease: a clinicopathologic entity? JAMA Neurol. 2013;70:571–9.PubMedPubMedCentralCrossRef
109.
Metadaten
Titel
α-Synuclein and Parkinsonism: Updates and Future Perspectives
verfasst von
Kaie Rosborough
Neha Patel
Lorraine V. Kalia
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 4/2017
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0737-y

Weitere Artikel der Ausgabe 4/2017

Current Neurology and Neuroscience Reports 4/2017 Zur Ausgabe

Sleep (M Thorpy and M Billiard, Section Editors)

Circadian Disruption Associated with Alzheimer’s Disease

Neuro-oncology (L Abrey, Section Editor)

Management of Elderly Patients with Glioblastoma

Sleep (M Thorpy and M Billiard, Section Editors)

Post-Traumatic Sleep-Wake Disorders

Movement Disorders (S Fox, Section Editor)

Subtypes of Parkinson’s Disease: What Do They Tell Us About Disease Progression?

Demyelinating Disorders (D N Bourdette & M Cameron, Section Editors)

CNS Demyelination with TNF-α Blockers

Epilepsy (CW Bazil, Section Editor)

Neuroimaging in Epilepsy

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise